Dartmouth College

University of California

William Marsh Rice University

Dean R Madden

Patrick R Cushing

Lars Vouilleme

Bruce D Hammock

Christophe H Morisseau

Rudolf Volkmer

Natalia Vasylieva

Jiexian Dong

Prisca Boisguérin

Mark R Spaller

Brian Vincent Popp

Zachary Thomas Ball

Nicholas P Gill

Carrie Ann Davison

Christopher D Bahl

Rituparna Kundu

Prisca Boisguearin

Rudolph Volkmer

Prisca Boinguérin

Provided are VHH or nanobodies that specifically bind to cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif), and uses thereof for diagnosis and treatment ofinfection.

Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)

Compositions and kits including an agent that inhibits the interaction between Disabled-2 and mutant CFTR proteins, optionally in combination with a CFTR corrector, CFTR potentiator, CAL inhibitor, mucolytic, anti-inflammatory agent or a combination thereof are provided as are methods for preventing or treating cystic fibrosis.

Dab2 inhibitors for the prevention and treatment of cystic fibrosis

Compositions, kits and methods for preventing or treating cystic fibrosis are provided, which include the use of a peptidomimetic that inhibits the interaction between CAL and mutant CFTR proteins.

Therapy and kit for the prevention and treatment of cystic fibrosis

The present invention provides a screening assay for identifying inhibitors ofCFTR Inhibitory Factor as well as compositions and methods for ameliorating or treating a respiratory disease such as cystic fibrosis or secondary infection thereof.

Compounds and methods for inhibiting Cif virulence factor

A combination therapy and kit including an agent that inhibit the interaction between CAL and mutant CFTR proteins, in combination with a CFTR corrector, CFTR potentiator, mucolytic, anti-inflammatory agent or a combination thereof are provided as is a method for preventing or treating cystic fibrosis.

Combination therapy and kit for the prevention and treatment of cystic fibrosis

Methods for targeting a protein by providing an inhibitor covalently linked to a rhodium(II) complex, introducing the inhibitor to the target protein and allowing the inhibitor and protein to interact. The rhodium(II) complex covalently linked to the inhibitor binds the target protein both inorganically and organically and forms stabilizing secondary contacts between the rhodium(II) complex and the protein.

Small molecule conjugates with dimetal species for protein inhibition

The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same to the cell surface.

Compositions and methods for inhibiting the interaction between CFTR and CAL

Growing community of inventors

Hanover, NH, United States of America

Dean R Madden